Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01752049 | Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept | PHASE1 | COMPLETED | 5 | — | — | May 1, 2013 | Aug 30, 2019 | Sep 21, 2023 | 1 | Canada |
Change in lesion area (compared with baseline measurement) of treated telangiectasia.
| Arm | Type | Description |
|---|---|---|
| Topical timolol maleate | ACTIVE_COMPARATOR | Drug: • Topical timolol maleate 0.5% drops * Topical timolol maleate 0.5% drops * Applied twice daily for 12 weeks (84 days) or until disappearance of lesions * Study drops will be applied to 3 cutaneous telangiectasias per patient telangiectasia per patient). |
| Placebo | PLACEBO_COMPARATOR | placebo saline drops -Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient. |
| Name | Type | Description |
|---|---|---|
| Topical timolol maleate | DRUG | * Topical timolol maleate 0.5% drops * Applied twice daily for 12 weeks (84 days) or until disappearance of lesions * Study drops will be applied to 3 cutaneous telangiectasias per patient |
| placebo saline drops | DRUG | Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to 1 cutaneous telangiectasias per patient. |
Inclusion Criteria: 1. Definite clinical or genetic diagnosis of HHT 2. Known ENG or ALK1 mutation (personal or familial) 3. Age\>=18 years 4. At least 5 typical (round/ovoid, not spider or linear) cutaneous telangiectasia (size range 2-5mm) on hands (not including lesions on over inter-phalangeal ...